Queensland researchers have discovered a potential treatment for the severe inflammation caused by infectious mosquito-borne diseases responsible for several outbreaks worldwide in the past decade.
Australian researchers are a step closer to understanding immune sensitivities to well-known, and commonly prescribed, medications. Many drugs are successfully used to treat diseases, but can also have harmful side effects. While it has been known that some drugs can unpredictably impact on the functioning of the immune system, our understanding of this process has been unclear.
IMB researchers have discovered a molecular trigger for inflammation that could lead to new treatments for rheumatoid arthritis, inflammatory bowel disease and neurodegenerative diseases. Professor Jennifer Stow said targeting this trigger - a protein called SCIMP, could reduce or ‘switch off’ inflammation.
The young inventor behind a UQ discovery that could benefit patients living with inflammatory diseases has been awarded the 2016 Research Australia Discovery Award.
Protagonist Therapeutics, a clinical-stage biopharmaceutical company founded on IMB research, has won Australian Company of the Year at the AusBiotech Industry Excellence Awards.
Inflazome Ltd, a company founded on research from The University of Queensland (UQ) and Trinity College Dublin, has closed a Series A financing round of up to €15 million (A$22 million).
